In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diagnostic Products Corp.

Division of Siemens Healthcare Diagnostics Inc.
www.dpcweb.com

Latest From Diagnostic Products Corp.

Genetic Biomarkers Offer New Hope In Identifying Prostate Cancer

Although physicians still struggle with the best ways to treat patients suspected of having prostate cancer, a new group of genetic-based tests could provide new tools that will help improve diagnostic accuracy. These new biomarkers offer hope in reducing the number of patients who receive unnecessary treatment for cancers that are not actually present in their bodies and for those cancers not aggressive enough to cause harm.

Medical Device Innovation

A Closer Look: Tips To Survive The Latest China Anti-Bribery Crackdown

As a bribery crackdown spreads into the broader health care industry in China, analysts offer advice on surviving the landscape and forecast its duration and intensity.

BioPharmaceutical Medical Device

Molecular Diagnostics Moves Into Prostate Cancer

While the PSA test is still widely recognized as a valuable prostate cancer screening tool, its dismal accuracy record has created an acute need for more effective and informative alternatives, and the field of molecular diagnostics, based on gene-based biomarkers, is leading the charge.

BioPharmaceutical Medical Device

Amersham Little Help to GE Healthcare in This Down Market

As befits this struggling economy, each of the Big Three in diagnostic imaging sounded downbeat in their 2008 year-end financial assessments. But more so than the other two, GE Healthcare focuses on the development of new imaging agents, owing to its acquisition of Amersham in late 2003. Ant that integration has been admittedly slow.
Medical Device
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register